Compare Incyte Corporation (INCY) vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 — how do they compare? Incyte Corporation trades at $117.94 (market cap $23.11B), while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $65.11. The key difference: Incyte Corporation is trading nearer its 52-week high, Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 nearer its low. Which is the better fit depends on your goals.
| INCY | SLVO | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $118.52 | $107.41 |
52-Week Low | $67.38 | $61.81 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SLVO trades at $62.98, up 0.99% on the day, but technical indicators signal a bearish trend with moving averages unanimously negative. Key financial ratios including P/E, P/S, and ROE are unavailable, limiting fundamental clarity. The stock faces resistance near $64 with support at $63, indicating tight trading boundaries amid weak momentum.
The outlook remains cautious due to bearish technicals and missing fundamental data. Risks include potential downside if support breaks, while any positive earnings or guidance could reverse sentiment. Investors require updated financial disclosures to assess valuation and growth prospects accurately.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →
